Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALAD | P13716 | 1/20 | 0.51 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | CTRC | Q99895 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11001807 | 0.84 | MAPT (0.54) | ALPLNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL6843818 | 0.84 | TP53 (0.44) | KMOCTRCNPC1RAB9AKDM4E | |
| SCHEMBL6668534 | 0.83 | ALAD (0.51) | ALADMCL1 | |
| SCHEMBL28093059 | 0.83 | CA12 (0.49) | CA12ALPLNPC1RAB9AKDM4E | |
| SCHEMBL8843416 | 0.82 | KMO (0.52) | KMONPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL13738641 | 0.82 | GSK3B (0.44) | ALADKMOCA12ALPLCTRC | |
| SCHEMBL369373 | 0.82 | NAPRT (0.46) | ALADKMONPC1RAB9AKDM4E | |
| SCHEMBL15083062 | 0.81 | MAPK14 (0.43) | KDM4EKMT2AALDH1A1MAPTCASP1 | |
| SCHEMBL8842795 | 0.80 | KMO (0.55) | KMOALPLNPC1RAB9AKDM4E | |
| SCHEMBL11000258 | 0.79 | ALPL (0.52) | ALPLNPC1RAB9AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299270-A1 | PROTEOSTASIS REGULATORS | Kineta, Inc. | 2020-09-24 | — | — | US | disclosed |
| EP-2707101-B1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS INC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9556166-B2 | Proteostasis regulators | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556166-B2 | Proteostasis regulators | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2012-12-13 | — | — | US | disclosed |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2012-12-13 | — | — | US | disclosed |
| WO-2012154967-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2012103113-A1 | PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C | GILEAD PHARMASSET, LLC (US) | 2012-08-02 | — | — | WO | disclosed |
| US-20040023807-A1 | 3-Arylisothiazoles and their use as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1289970-A1 | 3-ARYLISOTHIAZOLES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001087863-A1 | 3-ARYLISOTHIAZOLES AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-22 | — | — | WO | disclosed |
| US-4544752-A | TREATMENT OF GOUT; ANTIARTHRITIC AGENTS | ELI LILLY AND COMPANY (US) | 1985-10-01 | — | — | US | disclosed |
| EP-0048615-B1 | IMPROVEMENTS IN OR RELATING TO 3-ARYL-5-ISOTHIAZOLE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
| US-4346094-A | ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
| EP-0048615-A1 | Improvements in or relating to 3-aryl-5-isothiazole derivatives | ELI LILLY AND COMPANY (US) | 1982-03-31 | — | — | EP | disclosed |
| US-4261728-A | PREEMERGENT ACTIVITY | MONSANTO COMPANY (US) | 1981-04-14 | — | — | US | disclosed |
| US-4144047-A | SOYBEANS | MONSANTO COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299270-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | ALAD 159/4885KMO 4548/4885CA12 4544/4885 |
| US-20040023807-A1 | 3-Arylisothiazoles and their use as herbicides | DDT, HAX1, SULT1E1 | ALAD 1111/4885KMO 1141/4885CA12 3757/4885 |
| US-20120202794-A1 | COMPOUNDS | HAVCR2, MAVS, GOT2 | ALAD 2222/4885KMO 4575/4885CA12 4453/4885 |
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | ALAD 159/4885KMO 4548/4885CA12 4544/4885 |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | ALAD 159/4885KMO 4548/4885CA12 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.